Interchangeability: Have Biosimilar Makers Been Set Up To Fail?
Interchangeability: Have Biosimilar Makers Been Set Up To Fail?

Last week, the Journal of Managed Care & Specialty Pharmacy (JMCP) published research revealing current pharmacist perceptions on biosimilar naming. A number of media resources have leapt on the findings of this study as indicative of a potential danger the naming system alone could cause. But I feel as though these results speak to a greater issue with interchangeability that is worth examining a little more closely.

  • Anti-TNF Biosimilars In Europe: What Matters Beyond Price?
    Anti-TNF Biosimilars In Europe: What Matters Beyond Price?

    The recent introduction in Europe of biosimilar anti-tumor necrosis factor (anti-TNF) drugs has attracted considerable attention. Much of the commentary to date has centered on price, but price tells only part of the story. Structural and perceptual differences have led to considerable heterogeneity in the levels of discounting, access, and uptake throughout and even within European markets.

  • How To Succeed At Biosimilar Commercialization
    How To Succeed At Biosimilar Commercialization

    Steve Miller, CMO of Express Scripts emphasizes several key points for biosimilar makers to keep in mind as they work to establish their commercialization strategy.

  • How Patients Will Approach Your Biosimilar
    How Patients Will Approach Your Biosimilar

    Patients’ concerns — though they are to be expected when a new type of treatment emerges — can prove difficult to identify with on the biosimilar manufacturing side. But these concerns are important to understand when approaching FDA AdComs.

  • Biobetters: How Much Competition Should Biosimilar Makers Expect?
    Biobetters: How Much Competition Should Biosimilar Makers Expect?

    In the last few weeks, news stories have surfaced reminding the biosimilar industry that biobetters are alive and, for the most part, well. Overall, there are upwards of 500 biobetters in development worldwide. But should the biosimilar industry really be concerned about biobetters quashing the use of biosimilars?

  • Bioprocess Facility Design — Layout Rules And Configurations
    Bioprocess Facility Design — Layout Rules And Configurations

    The adoption of single-use systems (SUS) is allowing for a shift to smaller and more flexible facilities. This article explores modern facility design options and configurations, and best practices for building a facility around SUS process technology.

  • The Norwegian Biosimilar Phenomenon: From Biosimilar To “Biogeneric”
    The Norwegian Biosimilar Phenomenon: From Biosimilar To “Biogeneric”

    Following the recent Amgen and Sandoz FDA advisory committee meetings, which focused heavily on concerns about “non-medical switching,” Dr. Steiner Madsen’s often frank discussion on how switching contributed to biosimilar uptake in Norway provides reassurance and best practices for global biosimilar makers.

  • Biosimilars Pipeline Analysis: Many Products, More Competition Coming
    Biosimilars Pipeline Analysis: Many Products, More Competition Coming

    Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.

  • How “Consumer Reports” FDA Approvals Could Hurt Biosimilars
    How “Consumer Reports” FDA Approvals Could Hurt Biosimilars

    A recently published article in The Wall Street Journal proposes several changes to the FDA approval process. However, at a time when there should be more emphasis on accelerating biosimilar approval, this proposal very well could spell trouble for biosimilars. 

  • How To Establish Sample Sizes For Process Validation Using The Success-Run Theorem
    How To Establish Sample Sizes For Process Validation Using The Success-Run Theorem

    This article demonstrates two methods using the success-run theorem, which uses the confidence level (how sure we are) and reliability value (valid, consistent results) to determine appropriate statistically valid sample sizes for process validation.

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

  • A Wake-Up Call For APAC: FDA Requires Electronic Submissions By 2017

    The demand for generic drugs is skyrocketing. According to the US FDA, nearly 8 in 10 prescriptions filled in the United States are for generic drugs. Generic drugs can be considerably less expensive while typically providing the same level of effectiveness as brand name therapeutics. The demand is intensified by initiatives such as the Affordable Care Act that intend to lower the cost of national healthcare by compelling a move toward less expensive generics and biosimilars.

  • Six Myths About Serialization

    The global countdown to serialization compliance is well underway. Early adopters, such as Turkey and Argentina, required serialization as early as 2010, and were followed by others such as India, China and Korea.  Over the next three years, many other major markets will require adherence to their own serialization requirements, including the United States and the European Union. Expect that by 2018, serialization mandates will govern most of world’s drug supply. Biopharmaceutical companies that don’t comply will find it impossible to market their drugs in countries that have instituted serialization regulations.

  • Crystalomics: A Pathway Forward For Protein Crystallization

    Protein crystals have shown the potential to address many of the issues associated with high concentration/high viscosity solutions. While formulation and delivery challenges exist with crystallized formulations, they are not insurmountable. With access to the right level of expertise and experience, a company can manufacture its product using crystallization, thereby increasing patient compliance by offering an easier and faster form of drug delivery. 

  • Is your Complex Formulation Process Set Up for Success?

    This article discusses six major types of complex formulations as well as the important equipment and processes necessary to develop GMP-compliant processes.

  • Combination Products Deliver Patient Compliance

    In this e-book, you’ll find insight and advice from some of the top experts at Phillips-Medisize who have experience navigating the intertwined pathways of the drug and medtech industries that ultimately bring combination products to market.

More From Biosimilar...

TRAINING COURSES

FDA Quality Metrics Draft Guidance: What You Need to Know to be Prepared for Implementation August 25, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
The Power of Influencing – Achieving Patient-focused Outcomes to Guarantee Success August 29, 2016
1pm-2pm EDT, Online Training
Duration:  60 Minutes
Price:  $99 - Includes Bonus Handouts!
Analyzing and Understanding ISO 13485 Proposed Changes August 30, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Good Clinical Practices (GCP) Overview for Clinical Research Professionals - A Global Primer September 8, 2016
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Drug Development 101 – How A Drug Is Made September 13, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Update to ICH GCP E6 (R2) – Proposed Changes You Should Prepare For September 14, 2016
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
Applying Quality Risk Management (QRM) in Manufacturing – A Proactive Approach September 15, 2016
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Understanding & Implementing The New NIH & FDA Draft Clinical Trial Protocol Template September 20, 2016
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Single-Use Disposable Process Technologies - Best Practices And Advantages September 21, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
The Global Development Plan (GDP): Your Roadmap To Drug/Device Development September 23, 2016
1:00pm-2:30pm, EDT US
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
More Upcoming Courses
Anna Rose Welch article header

ARCHIVES

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.